+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Stem Cell Therapy Market 2018-2022 - Product Image

Global Stem Cell Therapy Market 2018-2022

  • ID: 4703294
  • Report
  • October 2018
  • Region: Global
  • 102 pages
  • TechNavio

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • Gilead
  • Novartis
  • Organogenesis
  • Vericel
  • MORE
The analysts forecast the Global Stem Cell Therapy Market to grow at a CAGR of 10.52% during the period 2018-2022.

Covered in this report

The report covers the present scenario and the growth prospects of the stem cell therapy market. To calculate the market size, the report considers the revenue generated by the application of stem cell therapy across the globe.

The market is divided into the following segments based on geography:
  • Americas
  • APAC
  • EMEA
The report, stem cell therapy market 2018-2022, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
  • Gilead
  • Novartis
  • Organogenesis
  • Vericel
Market drivers
  • Increasing awareness about stem cell therapy across the globe
  • For a full, detailed list, view the report
Market challenges
  • High cost of clinical trials
  • For a full, detailed list, view the report
Market trends
  • Rising cost of stem cell therapy procedure
  • For a full, detailed list, view the report
Key questions answered in this report
  • What will the market size be in 2022 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?
You can request one free hour of the analyst’s time when you purchase this market report. Details are provided within the report.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Gilead
  • Novartis
  • Organogenesis
  • Vericel
  • MORE
PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: MARKET LANDSCAPE
  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis
PART 05: PIPELINE ANALYSIS
  • Pipeline analysis
PART 06: MARKET SIZING
  • Market definition
  • Market sizing 2017
  • Market size and forecast 2017-2022
PART 07: FIVE FORCES ANALYSIS
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition
PART 08: MARKET SEGMENTATION BY TYPE
  • Segmentation by type
  • Comparison by type
  • Autologous transplants - Market size and forecast 2017-2022
  • Allogeneic transplants - Market size and forecast 2017-2022
  • Market opportunity by type
PART 09: CUSTOMER LANDSCAPE

PART 10: REGIONAL LANDSCAPE
  • Geographical segmentation
  • Regional comparison
  • Americas - Market size and forecast 2017-2022
  • EMEA - Market size and forecast 2017-2022
  • APAC - Market size and forecast 2017-2022
  • Market opportunity
PART 11: MARKET SEGMENTATION BY APPLICATION
  • Segmentation by application
PART 12: DECISION FRAMEWORK

PART 13: DRIVERS AND CHALLENGES
  • Market drivers
  • Market challenges
PART 14: MARKET TRENDS
  • Rise in costs
  • Reimbursement
  • Potential curative option for chronic diseases
  • Development of iPS cells
PART 15: VENDOR LANDSCAPE
  • Overview
  • Landscape disruption
PART 16: VENDOR ANALYSIS
  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Gilead
  • Novartis
  • Organogenesis
  • Vericel
PART 17: APPENDIX
  • List of abbreviations
List of Exhibits
Exhibit 01: Parent market
Exhibit 02: Global regenerative medicines market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: List of pipeline stem cell therapies
Exhibit 06: Market definition - Inclusions and exclusions checklist
Exhibit 07: Market size 2017
Exhibit 08: Validation techniques employed for market sizing 2017
Exhibit 09: Global stem cell therapy market - Market size and forecast 2017-2022 ($ mn)
Exhibit 10: Global stem cell therapy market - Year over year growth 2017-2022 (%)
Exhibit 11: Five forces analysis 2017
Exhibit 12: Five forces analysis 2022
Exhibit 13: Bargaining power of buyers
Exhibit 14: Bargaining power of suppliers
Exhibit 15: Threat of new entrants
Exhibit 16: Threat of substitutes
Exhibit 17: Threat of rivalry
Exhibit 18: Market condition - Five forces 2017
Exhibit 19: Global stem cell therapy market by type - Market share 2017-2022 (%)
Exhibit 20: Comparison by type
Exhibit 21: Global stem cell therapy market by autologous transplants - Market size and forecast 2017-2022 ($ mn)
Exhibit 22: Global stem cell therapy market by autologous transplants - Year over year growth 2017-2022 (%)
Exhibit 23: Global stem cell therapy market by allogeneic transplants - Market size and forecast 2017-2022 ($ mn)
Exhibit 24: Global stem cell therapy market by allogeneic transplants - Year over year growth 2017-2022 (%)
Exhibit 25: Market opportunity by type
Exhibit 26: Customer landscape
Exhibit 27: Global stem cell therapy market by region - Market share 2017-2022 (%)
Exhibit 28: Regional comparison
Exhibit 29: Stem cell therapy market in Americas - Market size and forecast 2017-2022 ($ mn)
Exhibit 30: Stem cell therapy market in Americas - Year over year growth 2017-2022 (%)
Exhibit 31: Top three countries in Americas
Exhibit 32: Stem cell therapy market in EMEA - Market size and forecast 2017-2022 ($ mn)
Exhibit 33: Stem cell therapy market in EMEA - Year over year growth 2017-2022 (%)
Exhibit 34: Top three countries in EMEA
Exhibit 35: Stem cell therapy market in APAC - Market size and forecast 2017-2022 ($ mn)
Exhibit 36: Stem cell therapy market in APAC - Year over year growth 2017-2022 (%)
Exhibit 37: Top three countries in Americas
Exhibit 38: Market opportunity
Exhibit 39: Types of accelerated approvals for stem cells
Exhibit 40: Vendor landscape
Exhibit 41: Landscape disruption
Exhibit 42: Vendors covered
Exhibit 43: Vendor classification
Exhibit 44: Market positioning of vendors
Exhibit 45: Gilead overview
Exhibit 46: Gilead - Business segments
Exhibit 47: Gilead - Organizational developments
Exhibit 48: Gilead - Geographic focus
Exhibit 49: Gilead - Key offerings
Exhibit 50: Novartis overview
Exhibit 51: Novartis - Business segments
Exhibit 52: Novartis - Organizational developments
Exhibit 53: Novartis - Geographic focus
Exhibit 54: Novartis - Segment focus
Exhibit 55: Novartis - Key offerings
Exhibit 56: Organogenesis overview
Exhibit 57: Organogenesis - Product segments
Exhibit 58: Organogenesis - Organizational developments
Exhibit 59: Organogenesis - Key offerings
Exhibit 60: Vericel overview
Exhibit 61: Vericel - Business segments
Exhibit 62: Vericel - Organizational developments
Exhibit 63: Vericel - Key offerings
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Gilead
  • Novartis
  • Organogenesis
  • Vericel
  • MORE
The author of the report recognizes the following companies as the key players in the global stem cell therapy market: Gilead, Novartis, Organogenesis, and Vericel.

Commenting on the report, an analyst from the research team said: “One trend affecting this market is the rising cost of stem cell therapy procedure. Stem cell transportation is a costly procedure and requires highly specialized tools and resources.”

According to the report, one driver influencing this market is the driven by the increasing awareness about stem cell therapy across the globe. Stem cells are cells that have the ability to divide and differentiate into almost every cell type in the body and used in surgery and medicine. With increasing advances in stem cell therapy research, the demand for stem cell therapy procedure is expected to witness a rise over the next few years.

Further, the report states that one challenge affecting this market is the high cost of clinical trials. The high cost of conducting clinical trials on stem cell therapy is high which poses a critical challenge to the growth of the market.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
  • Gilead
  • Novartis
  • Organogenesis
  • Vericel
Note: Product cover images may vary from those shown

Loading
LOADING...

Adroll
adroll